Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MME | P08473 | 3/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.43 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27355069 | 0.88 | KMT2A (0.57) | KMT2ALMNAPPARGPPARAACACB | |
| SCHEMBL25356249 | 0.88 | TDP1 (0.57) | KMT2AACACBTDP1PTPN1MEN1 | |
| SCHEMBL458048 | 0.88 | TDP1 (0.57) | KMT2AACACBTDP1PTPN1MEN1 | |
| SCHEMBL27095768 | 0.88 | TDP1 (0.57) | KMT2AACACBTDP1PTPN1MEN1 | |
| SCHEMBL23809602 | 0.87 | CES2 (0.44) | KMT2ALMNAPPARGTDP1PTPN1 | |
| SCHEMBL27266166 | 0.85 | PPARG (0.44) | KMT2ALMNAPPARGPPARAACACB | |
| SCHEMBL27355068 | 0.85 | KMT2A (0.53) | KMT2ALMNAPPARGPPARAACACB | |
| SCHEMBL25356783 | 0.85 | PLA2G10 (0.51) | KMT2ATDP1PTPN1MEN1L3MBTL1 | |
| SCHEMBL4943117 | 0.85 | GNPAT (0.49) | KMT2ALMNAPPARGPPARAACACB | |
| SCHEMBL25357735 | 0.85 | PLA2G10 (0.51) | KMT2ATDP1PTPN1MEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024015229-A1 | PROTEASE/ENZYME CLEAVABLE LINKER-PAYLOADS AND PROTEIN CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024006272-A1 | β-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF | SUTRO BIOPHARMA, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11708413-B2 | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates | SUTRO BIOPHARMA, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-10596270-B2 | Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates | SUTRO BIOPHARMA, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190144546-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20190083641-A1 | ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. | 2019-03-21 | — | — | US | disclosed |
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257709-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | CYP17A1, HSD17B7, SHBG | KMT2A 2712/4885LMNA 1536/4885PPARG 2401/4885 |
| US-11708413-B2 | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates | CD74, CD63, CD99 | KMT2A 2960/4885LMNA 2681/4885PPARG 3878/4885 |
| US-10596270-B2 | Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates | FOLR1, FOLR2, DHFR | KMT2A 2349/4885LMNA 3893/4885PPARG 3003/4885 |
| US-20190083641-A1 | ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | FOLR1, FOLR2, DHFR | KMT2A 2349/4885LMNA 3893/4885PPARG 3003/4885 |
| US-20190144546-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | CD74, CD99, CD63 | KMT2A 156/4885LMNA 2646/4885PPARG 4140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.